君圣泰医药HTD1801 III期临床试验已完成患者入组
财中社1月2日电君圣泰医药（02511）发布公告，宣布其自主研发的HTD1801针对2型糖尿病的III期临床试验已完成患者入组。该试验为随机、双盲、阳性药物平行对照的多中心、非劣效性研究，旨在评估HTD1801相对于达格列净在二甲双胍治疗后血糖控制不佳的成年T2DM患者中的疗效。试验计划入组358例受试者，目前已完成全部入组，预计2025年进行数据读出。
HTD1801是一种靶向肠－肝系统的口服抗炎及代谢调节剂，具有改善葡萄糖代谢、胰岛素抵抗、脂质代谢和肝脏炎症的潜力，旨在为T2DM等复杂代谢性疾病提供综合性解决方案。公司正在推进多项中后期临床试验，并持有全球知识产权。公告中强调，无法保证HTD1801最终会成功开发及上市，股东和潜在投资者需谨慎行事。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10